Point Biopharma
在场
Point Biopharma 的所有者是 Eli Lilly.
是其中之一......
- Forbes Global 2000 (#174);
- Fortune 500 (#127);
- Global Fortune 500 (#455);
- Russell 3000;
- S&P 500;
- TOB Iconic 10,000.
Eli Lilly 是一家在股票代码 LLY (US) 下上市的公司。
Eli Lilly 在 18 个国家有直接业务。Eli Lilly 拥有 25家子公司，其中包括 Dice Therapeutics、Eli Lilly APAC 和 Eli Lilly Argentina。
他们在：
涉及Eli Lilly的并购和融资。
- Eli Lilly has announced the acquisition of Point Biopharma (公布2023十二月5号).
- Eli Lilly has announced the acquisition of Point Biopharma (公布2023十月6号).
高管
查看带有其 4 名主要高管的组织结构图
Point Biopharma 搜索最多的简介
- Jessica Jensen, Executive Vice President, Clinical Development
- Bill Demers, Chief Financial Officer
- Robin Hallett, Senior Vice President, Discovery and Translational ...
高管在Eli Lilly变化
- Jon MoellerJon Moeller 将于202412月31作为 Director 加入公司 (新闻发布的2024十一月20号).
- Thomas FuchsThomas Fuchs 将于202410月21作为 Chief Artificial Intelligence Officer 加入公司 (新闻发布的2024十月9号).
- Marschall Runge, Director, 将于 20248月31 退休 (新闻发布的2024八月20号).
创建提醒
跟踪 Point Biopharma 的高管变动
生物技术
Eli Lilly 拥有 2,337 家竞争者，其中包括 Eurofins (卢森堡)、Lonza (瑞士) 和 Biogen (美国(美洲))。
Popular M&A news in 生物技术
- Aadi Bioscience 刚刚宣布为 100 筹款数百万美元。 (公布2024十二月20号).
- OraSure Technologies has announced the acquisition of Sherlock Biosciences (公布2024十二月20号).
- SiteOne Therapeutics 刚刚宣布为 100 筹款数百万美元。 (公布2024十二月20号).
生物技术 行业的其他推荐联系人
消息
Point Biopharma 的最新新闻稿
- Lantheus and POINT Biopharma Announce Positive Topline Results from Pivotal SPLASH Trial in Metastatic Castration-Resistant Prostate Cancer | POINT Biopharma
- POINT Biopharma Reports Third Quarter 2023 Financial Results and Provides Business Highlights | POINT Biopharma
- Lilly to Acquire POINT Biopharma to Expand Oncology Capabilities into Next-Generation Radioligand Therapies | POINT Biopharma
- POINT Biopharma and Athebio Announce Partnership to Develop Designed Ankyrin Repeat Protein Targeted Radioligands | POINT Biopharma
- POINT Biopharma Reports Second Quarter 2023 Financial Results and Provides Business Highlights | POINT Biopharma
- ITM and POINT Biopharma Expand Global Supply Agreement for n.c.a. Lutetium-177 | POINT Biopharma
- News & Company Announcements | POINT Biopharma
- POINT Biopharma and AdvanCell to Collaborate in the Development of Lead-212-Labeled Radioligands | POINT Biopharma
- POINT Biopharma Expands Its Research with Next-Generation Isotopes, Publishing New Preclinical Data at SNMMI’s Annual Congress | POINT Biopharma
- POINT Biopharma Announces Appointment of Dr. Bridget Martell to its Board of Directors | POINT Biopharma
- View more press releases Close
通过电子邮件
